05-03-2010: Tecan is collaborating with Arizona State University (ASU) to develop the Integrated Biodosimetry System, a prototype robotic system for rapid, high throughput screening to measure an individual’s level of exposure to radiation in the event of a radiological or nuclear incident. The project, involving several organizations, is supported by the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), and focuses on development of a system to enable more rapid triage of patients than is currently possible. Tecan, the ASU Biodesign Institute and its partners hope to demonstrate proof-of-concept of the platform technology by the end of the current contract period.
Dr Carl Yamashiro, principal investigator at ASU’s Biodesign Institute, explained: “The research team will work with Tecan on building a comprehensive high throughput system, allowing scientists to analyze blood samples from up to 2,000 people per day, per instrument. The beauty of our system is its versatility. Not only will we be developing a system for the effective response to a nuclear or radiological event that could affect a large population, but the high throughout platform can also be used to advance genomics testing and other routine laboratory procedures that measure gene expression levels.”
Tecan is collaborating with Arizona State University (ASU) to develop the Integrated Biodosimetry System, a prototype robotic system for rapid, high throughput screening to measure an individual’s level of exposure to radiation in the event of a radiological or nuclear incident. The project ... more
Arizona State Univeristy scientist N.J. Tao and his colleagues at the Biodesign Institute have hit on a new, versatile method to significantly improve the detection of trace chemicals important in such areas as national security, human health and the environment.
Tao's team was able to det ... more
Faster sequencing of DNA holds enormous potential for biology and medicine, particularly for personalized diagnosis and customized treatment based on each individual's genomic makeup. At present however, sequencing technology remains cumbersome and cost prohibitive for most clinical applica ... more